Healthcare Experts Not Surprised at Avandia Findings

The Los Angeles Times (7/2, Lazarus) reported that, following recent research linking Avandia (rosiglitazone) to increased heart risks, healthcare experts and federal regulators are not surprised.  Sidney Wolfe, director of health research for the advocacy group Public Citizen, stated that a key problem with the FDA’s drug-approval process is that a much greater emphasis is placed on the effectiveness of a medication than on its safety.